>>Peptides>>GIP (1-30) amide,Human acetate

GIP (1-30) amide,Human acetate

Catalog No.GC60175

GIP(1-30) 아미드, 인간 아세테이트는 포도당 의존성 인슐린 분비 촉진 폴리펩티드(GIP) 단편입니다.

Products are for research use only. Not for human use. We do not sell to patients.

GIP (1-30) amide,Human acetate Chemical Structure

Size 가격 재고 수량
1mg
US$139.00
재고 있음
5mg
US$417.00
재고 있음
10mg
US$695.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GIP (1-30) amide,Human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide (Human) dose-dependently promotes insulin secretion over the range 10-9-10-6 M[1].

The glucose-dependent action of Glucose-dependent insulinotropic polypeptide (GIP) on pancreatic β-cells has attracted attention towards its exploitation as a potential drug for type 2 diabetes. In a 50% aqueous trifluoroethanol solvent, GIP(1-30) amide has an α-helical structural region from F6 to A28. The structures calculated for GIP(1-30) amide remain within one family of conformations and the level of agreement between the structures demonstrated the ordered arrangement[1].

[1]. AlaÑa I, et al. NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide. Biochem Biophys Res Commun. 2004 Dec 3;325(1):281-6.

리뷰

Review for GIP (1-30) amide,Human acetate

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GIP (1-30) amide,Human acetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.